The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer

[1]  Xixi Li,et al.  Different prognostic effect of surgery, radiation and chemotherapy in pediatric medulloblastoma less and over three years old: A Surveillance, Epidemiology, and End Results (SEER) analysis , 2021 .

[2]  W. Pang,et al.  MiR‐127 attenuates adipogenesis by targeting MAPK4 and HOXC6 in porcine adipocytes , 2019, Journal of cellular physiology.

[3]  LeiChen,et al.  YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. , 2019, Cancer letters.

[4]  Hongwei Li,et al.  miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1 , 2019, Cell cycle.

[5]  E. Hanse,et al.  MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1 , 2019, Nature Communications.

[6]  Jun Wang,et al.  miR-1260b, mediated by YY1, activates KIT signaling by targeting SOCS6 to regulate cell proliferation and apoptosis in NSCLC , 2019, Cell Death & Disease.

[7]  N. Karin.  Chemokines and cancer: new immune checkpoints for cancer therapy. , 2018, Current opinion in immunology.

[8]  Y. Miao,et al.  YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway , 2018, International journal of cancer.

[9]  A. Biankin,et al.  Chemotherapy and radiotherapy for advanced pancreatic cancer. , 2018, The Cochrane database of systematic reviews.

[10]  Y. Tao,et al.  Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer , 2018, Molecular Cancer.

[11]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[12]  Y. Miao,et al.  Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis. , 2017, Cancer letters.

[13]  Hai-jiao Yan,et al.  MiR-629 promotes human pancreatic cancer progression by targeting FOXO3 , 2017, Cell Death and Disease.

[14]  E. Giovannetti,et al.  Drug resistance in pancreatic cancer: Impact of altered energy metabolism. , 2017, Critical reviews in oncology/hematology.

[15]  Lei Zhang,et al.  Overexpression of miR-584-5p inhibits proliferation and induces apoptosis by targeting WW domain-containing E3 ubiquitin protein ligase 1 in gastric cancer , 2017, Journal of experimental & clinical cancer research : CR.

[16]  W. Burns,et al.  Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis , 2017, Annals of Surgical Oncology.

[17]  J. Frasor,et al.  Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas , 2015, PloS one.

[18]  W. Lau,et al.  The concept and controversy of retroperitoneal nerve dissection in pancreatic head carcinoma (Review). , 2015, International journal of oncology.

[19]  H. Friess,et al.  Neural plasticity in pancreatitis and pancreatic cancer , 2015, Nature Reviews Gastroenterology &Hepatology.

[20]  Yanyan Wu,et al.  MiR-548-3p functions as an anti-oncogenic regulator in breast cancer. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  L. Moldawer,et al.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer , 2015, Cancer Immunology, Immunotherapy.

[22]  Kwang-Kyun Park,et al.  Loss of RUNX3 expression promotes cancer‐associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non‐small cell lung cancer , 2015, The Journal of pathology.

[23]  Hui Ling,et al.  MicroRNA Processing and Human Cancer , 2015, Journal of clinical medicine.

[24]  elliot k fishman,et al.  Pancreatic cancer surgery: past, present, and future. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[25]  L. Wood,et al.  Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis , 2015, Clinical Cancer Research.

[26]  Andrew D. Luster,et al.  Chemokines in Cancer , 2014, Cancer Immunology Research.

[27]  T. Xing,et al.  MiRNA-548ah, a Potential Molecule Associated with Transition from Immune Tolerance to Immune Activation of Chronic Hepatitis B , 2014, International journal of molecular sciences.

[28]  M. Heikenwalder,et al.  Inflammatory chemokines and metastasis—tracing the accessory , 2014, Oncogene.

[29]  Y. Miao,et al.  Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism , 2014, Molecular Cancer.

[30]  W. Curran,et al.  Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. , 2014, Cancer research.

[31]  M. Menger,et al.  Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer , 2014, Clinical & Experimental Metastasis.

[32]  F. Balkwill,et al.  Cancer cell‐derived lymphotoxin mediates reciprocal tumour–stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts , 2014, The Journal of pathology.

[33]  A. Lowy,et al.  Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells , 2012, Journal of Translational Medicine.

[34]  Peiyong Jiang,et al.  A Novel YY1-miR-1 Regulatory Circuit in Skeletal Myogenesis Revealed by Genome-Wide Prediction of YY1-miRNA Network , 2012, PloS one.

[35]  C. Deng,et al.  Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation , 2012, Oncogene.

[36]  Tiziana Bonaldi,et al.  Yin Yang 1 extends the Myc-related transcription factors network in embryonic stem cells , 2011, Nucleic acids research.

[37]  C. Napoli,et al.  CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy , 2010, Proceedings of the National Academy of Sciences.

[38]  O. Boyman,et al.  The role of chemokines in cancer immune surveillance by the adaptive immune system. , 2009, Seminars in cancer biology.

[39]  S. Weitzman,et al.  p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc , 2008, Oncogene.

[40]  D. Corey,et al.  Antisense transcripts are targets for activating small RNAs , 2008, Nature Structural &Molecular Biology.

[41]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[42]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[43]  Yang Shi,et al.  Transcriptional repression by YY1, a human GLI-Krüippel-related protein, and relief of repression by adenovirus E1A protein , 1991, Cell.

[44]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[45]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.